



Short communication

An analytical method for the measurement of acid metabolites of tryptophan-NAD pathway and related acids in urine

Xiangjun Liao^a, Jiping Zhu^{a,*}, Mamoon Rubab^a, Yong-lai Feng^a, Raymond Poon^b^a Exposure and Biomonitoring Division, Health Canada, 50 Colombine Driveway, Ottawa, Canada K1A 0K9^b Hazard Identification Division, Health Canada, 50 Colombine Driveway, Ottawa, Canada K1A 0K9

ARTICLE INFO

Article history:

Received 25 November 2009

Accepted 10 February 2010

Available online 23 February 2010

Keywords:

Quinolinic acid
Picolinic acid
Nicotinic acid
Pyridylacetic acid
Urine
Mixed-mode SPE
LC/MS

ABSTRACT

An analytical method has been developed for the measurements of five urinary acids namely, quinolinic acid, picolinic acid, nicotinic acid, 2-pyridylacetic acid and 3-pyridylacetic acid. The high performance liquid chromatograph–electrospray ionization mass spectrometry was operated in positive polarity under selected ion monitoring mode, with a column flow rate of 0.2 ml/min and an injection volume of 20 μ l. The method used isotope-labelled picolinic acid (PA-d₄) and nicotinic acid (NA-d₄) as internal standards for the quantification. The sample preparation involved parallel use of two different types of mixed-mode solid phase extraction cartridges (Strata-X-AW for the extraction of quinolinic acid, and Strata-X-C for the remaining acids). Quantitative analysis of five target acids in several human and rat urine samples showed that the levels of acids were relatively uniform among rats while larger variations were observed for human samples.

Crown Copyright © 2010 Published by Elsevier B.V. All rights reserved.

1. Introduction

Rapid and sensitive measurements of acid metabolites and intermediates in the tryptophan-nicotinamide adenine dinucleotide (NAD) pathway have important contributions to make in clinical and biological research. Quinolinic acid (QA), a metabolite of tryptophan catabolism, is believed to be involved in the pathogenesis of several major inflammatory neurological diseases [1,2]. Picolinic acid (PA), another tryptophan metabolite, is a potent metal-binding ligand with a strong capacity to bind iron and other essential mineral elements [3]. The water soluble vitamin nicotinic acid (NA) is a primary substrate for the biosynthesis of NAD, a cofactor in energy metabolism, through the tryptophan-NAD pathway, and serves also as a therapeutic agent for its lipid-lowering properties [4]. Recent studies have reported that, in addition to elevation in fatty acid β -oxidation, activation of peroxisome proliferators activated receptor α (PPAR- α) also modulated the tryptophan-NAD pathway, probably through the inhibition of the key enzyme 2-amino 3-carboxymuconate 6-semialdehyde decarboxylase [5,6]. As a result, chemicals that are PPAR- α agonists have been reported to induce marked increases in the excretion of QA, NAD and other tryptophan-NAD pathway metabolites [5–8]. The metabolites of tryptophan-NAD pathway including QA, PA and NA were primarily

measured in urine to offer a continuous and non-invasive method to study PPAR- α agonist effects *in vivo* including kinetics and mechanisms of action of PPAR- α agonists and to screen chemicals with potential agonist activity.

Although several methods have been developed for the urinary metabolic acids in the tryptophan-NAD pathway [9–24], they are either limited to the analysis of a single acid in urine samples or to the instrumental separation and detection only. The objective of this study was to develop a LC/MS based method for the concurrent measurement of QA, PA and NA in urine samples. We also included 3-pyridylacetic acid (3-PAA) and 2-pyridylacetic acid (2-PAA) in the measurements. Although not being part of the tryptophan-NAD pathway metabolites, 3-PAA [25,26] has been identified as one of the urinary metabolites in rats following ingestion of nuts and grains rich in myosmine and can serve as an indicator of food consumption by rats during the animal experiment [27]. 2-PAA, a major metabolite of vestibular disorders drug betahistine [17], is an isomer of 3-PAA that elutes closely to 3-PAA on the liquid chromatogram. Monitoring 2-PAA in the method will ensure good separation of 3-PAA.

2. Material and methods

Quinolinic acid (QA, 99%), picolinic acid (PA, 99%), nicotinic acid (NA, 98%), 2-pyridylacetic acid hydrochloride (2-PAA, 99%), 3-pyridylacetic acid hydrochloride (3-PAA, 98%), trifluoroacetic acid (TFA) (99%), acetic acid (AA, 99.7%) and ammonium hydroxide

* Corresponding author. Tel.: +1 613 946 0305.

E-mail address: jiping.zhu@hc-sc.gc.ca (J. Zhu).

(NH₃, 28–30%) were purchased from Sigma–Aldrich Company Ltd. (Oakville, ON, Canada). Internal standards PA-d₄ (98 atom %D), and NA-d₄ (98 atom %D) were from C/D/N Inc. (Montreal, QC, Canada). Formic acid (FA, 99%) was from ACROS Organics (New Jersey, USA). OmniSolv acetonitrile and methanol were HPLC grade and purchased from EMD[®] Chemicals Inc (New Jersey, USA). Water used in the study was in-house generated deionized (DI) water. The Strata-X-C cartridge (200 mg, 33 μm polymeric strong cation mixed-mode solid phase adsorbent) and Strata-X-AW cartridge (200 mg, 33 μm polymeric weak anion mixed-mode solid phase adsorbent) were both from Phenomenex (Torrance, CA, USA).

All stock standard solutions (1 mg/ml) were made in water. Subsequent calibration standard solutions were made from stock solution using 0.3% aqueous TFA. Spiking solution (100 ng/μl) was prepared by diluting 1 mg/ml stock solution with water. Blanks were made of 500 μl water. Lab control samples constituted either (a) 490 μl water and 10 μl of spiking solution for Strata-X-C cartridge for extracting PA, NA, 2-PAA and 3-PAA, or (b) 400 μl water and 100 μl of spiking solution for Strata-X-AW cartridge for extracting QA.

Human urine samples were donated by volunteers and rat urine samples were the control samples (rats that were fed with diet only) from an in-house animal study. The samples were thoroughly mixed by vortex, followed by centrifuging for 2 min at 1800 rpm. Finally 500 μl of the upper layer solution was pipetted into a 1.5-ml Eppendorf vial and mixed with 500 μl 3% aqueous FA by vortex.

The extraction of QA from urine samples was carried out using Strata-X-AW cartridges. The cartridge was conditioned with 4 ml of methanol and 4 ml of water prior to sample loading. After sample loading, the cartridge was washed with 4 ml of 1% aqueous FA, followed by 4 ml of methanol. QA was then eluted with 2.5 ml of 3 M aqueous ammonia. The eluate was concentrated to 0.5 ml under a nitrogen stream. After mixing with 50 μl of TFA, 50 μl of 100 ng/μl of the internal standards (PA-d₄ and NA-d₄) and 4.4 ml of water, the resulting solution with a final volume of 5 ml was ready for HPLC–MS analysis.

The extraction of PA, NA, 2-PAA and 3-PAA from urine samples was performed using Strata-X-C cartridges. The cartridge was conditioned with 2 ml of methanol, 2 ml of 1:1 mixture of methanol and 50% aqueous AA, and 2 ml of 50% aqueous AA prior to sample loading. The loaded cartridge was washed with 4 ml of water, followed by 4 ml of methanol. The acids were then eluted by 2.5 ml of 3 M aqueous ammonia. The eluate was concentrated to 0.5 ml under a nitrogen stream. After mixing with 20 μl of TFA and 5 μl of

Table 1
Time profile of HPLC mobile phase.

Time (min)	A (0.3% TFA in water) (%)	B (0.3% TFA in acetonitrile) (%)	C (water) (%)
0	100	0	0
7	95	5	0
7.5	61	5	34
14	61	5	34
14.5	0	100	0
25	0	100	0
26	100	0	0
46	100	0	0

100 ng/μl of the internal standards (PA-d₄ and NA-d₄), the resulting solution with a final volume of 0.5 ml was ready for HPLC–MS analysis. After the determination of PA and NA, the extracts were diluted 10 times to determine the levels of PAAs.

An Agilent 1100 series LC/MS (Agilent Technologies Inc., Waldbronn, Germany) equipped with a Primesep[®] 100 analytical column (5 μm, 150 mm × 2.1 mm) (SIELC Technologies, Inc., Prospect Heights, IL, USA) was used for the analysis. Column temperature was set at 30 °C. Injection volume was 20 μl. Elution was performed at a flow rate of 0.20 ml/min using a mobile system consisting of solutions A (0.3% TFA in water), B (0.3% TFA in acetonitrile) and C (water). The time profile of the HPLC mobile phase is listed in Table 1.

The MS was operated in positive ion mode in selected ion monitoring (SIM) modes (*m/z*: 168 for QA, 124 for NA and PA, 128 for NA-d₄ and PA-d₄, and 138 for 2-PAA and 3-PAA). The values of the fragmentor, step size, and gain, were set at 50, 0.1 and 3.0, respectively. The MS capillary voltage was maintained at 3500 V. Nitrogen was used as the nebulizer gas at 30 psi and the drying gas was delivered at 10 l/min.

Daily instrument calibration (from 0.02 to 62.5 ng/μl) was run at the beginning of each batch. The calibration curve was derived from the concentration ratios of standard over internal standard versus the peak area ratios according to the following equation: $C_s/C_i = a \times (A_s/A_i)^b$, where C_s is the concentration of the standard and C_i the internal standard; A_s and A_i are peak areas of the standard and the internal standard, respectively; a and b are constants determined from the regression. PA-d₄ was used for quantifying QA and PA while NA-d₄ for the rest of the three acids. For samples, the concentration of the target analyte (C_s) can be calculated from its peak area (A_s), response of the inter-




Fig. 1. Structures and pKa values of target acids.

Table 2

Method performance (numbers in parentheses after the value indicate the relative standard deviation (%RSD) of the mean values that preceded the parentheses).

		QA	PA	NA	3-PAA	2-PAA
Calibration ^a	<i>a</i>	3.9069 (4.5%)	1.1094 (2.1%)	0.9569 (2.8%)	0.7504 (8.0%)	0.9411 (5.6%)
Calibration ^a (<i>n</i> = 6, over 6 days)	<i>b</i>	0.9134 (1.5%)	0.9630 (0.8%)	0.9786 (1.3%)	0.9942 (1.3%)	1.0198 (0.9%)
	<i>r</i> ²	0.9972 (0.2%)	0.9999 (0.0%)	0.9998 (0.0%)	0.9996 (0.0%)	0.9990 (0.1%)
IDL (ng/μl)		0.02	0.01	0.01	0.02	0.02
%Recovery from lab control (<i>n</i> = 6)		92(15%)	103(13%)	69(9%)	49(20%)	98(14%)
MDL (mg/ml)		0.2 ^{**}	0.01	0.01	0.4 ^{**}	0.02
Measured value (ng/μl) of 2.5 ng/μl standard (<i>n</i> = 6)		2.50 (11%)	2.44 (0.8%)	2.48 (1.2%)	2.21 (3.4%)	2.59 (11%)

^a Calibration curve: $C_s/C_i = a \times (A_s/A_i)^b$, where C_s is concentration of standard while C_i for internal standard; A_s is peak area of standard while A_i for internal standard. The calibration range was 0.02–62.5 ng/μl.

^{**} Based on 10 times dilution of the sample.

nal standard (A_i) and the concentration of the internal standard (C_i).

One laboratory blank and one laboratory control were included in each analytical batch. The recoveries of the analytes were estimated by the recovery of the laboratory control samples. A standard at mid-point level (2.5 ng/μl) was repeated once at the end of the analytical run to monitor the performance stability of the instrument. Matrix effect on ESI–MS was also evaluated using diluted and non-diluted samples.

3. Results and discussion

Four types of solid phase extraction (SPE) cartridges, Isolute EC18 (Biotage, USA), Strata-X (Phenomenex, Torrance, CA, USA), Strata-X-C and Strata-X-AW were tested in this study for the extraction of the five target acids. Isolute EC18 and Strata-X could not retain the target acids, likely due to the polar and zwitterionic nature of these acids. The structures and pKa values of the target

acids are given in Fig. 1. These acids are negatively charged at the carboxylic acid group at high pH, positively charged at the pyridinyl nitrogen at low pH, while form zwitterions (positive charge on nitrogen and negative charge on the carboxylic acid at the same time) at pH values in between.

Strata-X-C and Strata-X-AW are mixed-mode cartridges containing both reverse-phase adsorbent of the strata-X and an adsorbent of ion exchanger nature (C for cation exchanger and AW for weak anion exchanger). They provide much better retaining power for organic compounds in ionized form. However, despite of many different conditions being tested, neither Strata-X-C nor Strata-X-AW alone could retain all five target acids effectively. It was therefore necessary to use two types of cartridges to process urine samples in order to extract all five target acids for instrumental analysis. In this case, two aliquots of the same urine sample were prepared and each was handled with the respective SPE cartridge. Similar to the situation in sample preparation, instrument separation of all five target acids was only achieved on a




Fig. 2. Typical LC/MS selected ion chromatograms of five acids in rat urine samples.

Table 3
Concentration ($\mu\text{g/ml}$) of acids in rat and human urine samples.

Subjects	QA	PA	NA	3-PAA
Rat urine ($n=7$)				
Min	25.1	0.08	0.85	39.1
Max	34.4	0.16	2.24	55.7
Average	30.3	0.11	1.52	51.3
RSD (%)	10	23	31	11
Median	31.0	0.11	1.51	53.7
Human urine ($n=9$)				
Min	0.78	0.07	ND	1.3
Max	17.0	0.26	0.24	16.3
Average	6.3	0.16	0.04	7.09
RSD (%)	84	46	191	72
Median	4.37	0.14	ND	7.72

mixed-mode reverse-phase column containing acidic ion-pairing groups.

It is well known that LC/MS response may be influenced by the nature of the sample matrix, especially when the matrix is complex [28,29]. This matrix effect could be minimized by diluting the samples. Under our instrument conditions, we have found severe matrix effect for QA (>80% suppression in measured values) in the 0.5 ml final solution from original 0.5 ml of urine. The matrix effect became much less (<15%) if the final solution was diluted to 2.5 ml, and no noticeable matrix effect was observed when the final solution was further diluted to 5 ml. Matrix effect was much smaller for 3-PAA (about 25%), and no matrix effect was observed for the other target acids. Therefore, the measurement of QA and 3-PAA was carried out with a final solution of 5 ml while the other acids were analyzed with a final volume of 0.5 ml.

The method performance is summarized in Table 2. Typical chromatograms of rat urine samples are shown in Fig. 2. 2-PAA was not detected in either human or rat urine samples, which is in agreement with the literature where 2-PAA was chosen as an internal standard to identify QA in a human urine sample by capillary electrophoresis [23]. Seven urine samples collected from rats fed with animal diet during one of our in-house animal studies showed a fairly uniform concentration of the target acids, evidenced by the small variation among the seven rat urine samples (Table 3). Since these rats were fed and treated the same way, similar results among the rat urine samples were expected. The measured NA concentrations (mean = 1.52 $\mu\text{g/ml}$) in rat urine are in good agreement with those reported in the literature [30]. PA levels in rat urine samples was an order of magnitude lower (mean = 0.11 $\mu\text{g/ml}$) compared to NA and QA.

The concentrations of acids in human urine samples were more variable (Table 3). PA levels in human urine (mean = 0.16 $\mu\text{g/ml}$) were very similar to those in rat urine. Some degree of variation of PA levels (0.07–0.26 $\mu\text{g/ml}$) was observed among human samples.

Compared to rat urine, human urine contained much lower NA levels (from non-detected to 0.24 $\mu\text{g/ml}$). Similar to the findings in rat urine, QA and 3-PAA were the two major target acids detected in humans. However the levels of these two acids varied significantly among the human urine samples.

Acknowledgments

The authors gratefully acknowledge the financial support from Canadian government for this study. The authors would like to thank Marc Rigden for conducting in-house animal studies and providing rat urine samples for this project.

References

- [1] G.J. Guillemin, V. Meininger, B.J. Brew, *Neurodegener. Dis.* 2 (2005) 166.
- [2] T.W. Stone, *Toxicol.* 39 (2001) 61.
- [3] G.W. Evans, P.E. Johnson, *Pediatr. Res.* 14 (1980) 876.
- [4] J. McKenney, *Arch. Intern. Med.* 164 (2004) 697.
- [5] M. Shin, M. Ohnishi, S. Iguchi, K. Sano, C. Umezawa, *Toxicol. Appl. Pharmacol.* 158 (1999) 71.
- [6] M. Shin, I. Kim, Y. Inoue, S. Kimura, F.J. Gonzalez, *Mol. Pharmacol.* 70 (2006) 1281.
- [7] T. Fukuwatari, Y. Suzuki, E. Sugimoto, K. Shibata, *Biosci. Biotechnol. Biochem.* 61 (2002) 2687.
- [8] T. Fukuwatari, S. Ohsaki, S.I. Fukuoka, R. Sasaki, K. Shibata, *Toxicol. Sci.* 81 (2004) 302.
- [9] H.M. Liebich, C. Foerst, *J. Chromatogr. B* 525 (1990) 1.
- [10] M. Ken-ichi, O. Kiyo, I. Fumio, W. Mitsuo, *Anal. Chim. Acta* 302 (1995) 179.
- [11] C. Iwaki, T. Ogiso, H. Hayashi, E.T. Lin, L.Z. Benet, *J. Chromatogr. B* 661 (1994) 154.
- [12] M.R.L. Stratford, M.F. Dennis, *J. Chromatogr. B* 582 (1992) 145.
- [13] C.Z. Chuang, F.A. Ragan, C. Prasad, *J. Chromatogr. B* 534 (1990) 13.
- [14] F. Guler, C. Bachmann, *Clin. Chem.* 40 (1994) 862.
- [15] J.D. Shoemaker, W.H. Elliott, *J. Chromatogr. B* 562 (1991) 125.
- [16] G.A. Smythe, O. Braga, B.J. Brew, R.S. Grant, G.J. Guillemin, S.J. Kerr, D.W. Walker, *Anal. Biochem.* 301 (2002) 21.
- [17] X.Y. Chen, D.F. Zhong, J.L. Duan, B.X. Yan, *Xenobiotica* 33 (2003) 1261.
- [18] K.T. McManus, J.D. DeBethizy, D.A. Garteiz, G.A. Kyrematen, E.S. Vesell, *J. Chromatogr. Sci.* 28 (1990) 510.
- [19] A. Fardet, R. Llorach, J.F. Martin, C. Besson, B. Lyan, E. Pujos-Guillot, A. Scalbert, *J. Proteome Res.* 7 (2008) 2388.
- [20] A.C. Li, Y.L. Chen, H. Junga, W.Z. Shou, X. Jiang, N. Wang, *Chromatographia* 58 (2003) 723.
- [21] D.N. Mallett, S. Dayal, G.J. Dear, A.J. Pateman, *J. Pharmaceut. Biomed. Anal.* 41 (2006) 510.
- [22] E.L. Sainio, P.H. Hynninen, *J. Chromatogr. B* 420 (1987) 263.
- [23] P.L. Weber, M. Malis, S.D. Palmer, T.L. Klein, S.M. Lunte, *J. Chromatogr. B* 697 (1997) 263.
- [24] E.E.K. Baidoo, M.R. Clench, R.F. Smith, L.W. Tetler, *J. Chromatogr. B* 796 (2003) 303.
- [25] G. Ratti, E. DeFina, *Lancet* 2 (1959) 917.
- [26] M.G. Rowlands, S.E. Barrie, F. Chan, J. Houghton, M. Jarman, R. McCague, G.A. Potter, *J. Med. Chem.* 38 (1995) 4191.
- [27] W. Zwickenkflug, S. Tyroller, E. Richter, *Drug. Metabol. Dispos.* 33 (2005) 1648.
- [28] M. Jemal, A. Schuster, D.B. Whigan, *Rapid Commun. Mass Spectrom.* 17 (2003) 1723.
- [29] S. Wang, M. Cyronak, E. Yang, *J. Pharmaceut. Biomed. Anal.* 43 (2007) 701.
- [30] G. Mccreanor, D.A. Bender, *Br. J. Nutr.* 56 (1986) 577.